THURSDAY, Sept. 12, 2024 (HealthDay News) -- It could be a real breakthrough for people at risk for HIV infection: A shot ...

More encouraging news has been announced about the new, twice-yearly PrEP injection currently undergoing trials. Lenacapavir ...

In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...

The findings reveal that administering Depemokimab twice yearly significantly lowers the annualized rate of asthma ...

we can deliver twice-yearly lenacapavir for PrEP worldwide, for all those who want or need PrEP.” While the results are good news, the drug is expensive. The National Institutes of Health have ...

Lenacapavir, a twice-yearly injectable antiretroviral, reduced the risk of HIV infection by 96% in a large study of gay and bisexual men and gender diverse people, according to a Gilead Sciences ...

Llenacapavir, a new HIV prevention injection, has been shown to have a 96% efficacy rate against the spread of the virus.

An injected antiviral medicine, taken twice a year, appears to offer at-risk people near-complete protection against HIV Gilead's lenacapavir was 96% effective in preventing new infections, when ...